Newsroom

GINEVRA--(BUSINESS WIRE)--OM Pharma presenterà i risultati preliminari dello studio REACH al congresso della European Academy of Allergy and Clinical Immunology (EAACI). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido....

GENÈVE--(BUSINESS WIRE)--OM Pharma zal preliminaire resultaten uit de REACH-studie onthullen tijdens het EAACI-congres (European Academy of Allergy & Clinical Immunology Congress). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is....

BOSTON--(BUSINESS WIRE)--Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston...

MISSISSAUGA, Ontario & COQUITLAM, British Columbia--(BUSINESS WIRE)--Imperial Dade Canada, a leading distributor of food service packaging, janitorial supplies, industrial products, and facility solutions, today announced the successful completion of its previously announced acquisition of Enterprise Paper Holdings, Ltd. (“Enterprise Paper” or the “Company”). Financial terms of the private transaction were not disclosed. Founded in 1973, Enterprise Paper is a Canadian-owned distributor of paper...

MISSISSAUGA, Ontario & COQUITLAM, Colombie-Britannique--(BUSINESS WIRE)--Imperial Dade Canada, l’un des principaux distributeurs d’emballages pour la restauration, de fournitures d’entretien, de produits industriels et de solutions pour les installations, a annoncé aujourd’hui la finalisation de l’acquisition précédemment annoncée de Enterprise Paper Holdings, Ltd. (« Enterprise Paper » ou la « Société »). Les modalités financières de cette transaction privée n’ont pas été divulguées. Fondée en...

WILMINGTON, Del.--(BUSINESS WIRE)--  De resultaten van Incyte’s cruciale fase 3-studie frontMIND naar de combinatiebehandeling met tafasitamab (Monjuvi® /Minjuvi®) werden gepresenteerd tijdens de plenaire sessie van het congres van de European Hematology Association (EHA) in 2026 en toonden een langere progressievrije overleving aan Incyte (Nasdaq:INCY) heeft vandaag positieve resultaten bekendgemaakt van de cruciale fase 3-studie frontMIND, waarin de werkzaamheid en veiligheid werden geëvaluee...

WILMINGTON, Delaware--(BUSINESS WIRE)--  I risultati dello studio clinico pivotale di Fase 3 frontMIND di Incyte sulla combinazione di Tafasitamab (Monjuvi®/Minjuvi®) presentati in occasione della sessione plenaria del congresso 2026 della European Hematology Association (EHA) hanno indicato un prolungamento della sopravvivenza libera da progressione Incyte (Nasdaq:INCY) ha annunciato oggi i risultati positivi ottenuti dallo studio clinico pivotale di Fase 3 frontMIND che valuta l'efficacia e l...

LONDON--(BUSINESS WIRE)--  Xtrackers II Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 12 June 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and t...

WILMINGTON, Delaware--(BUSINESS WIRE)--  Los resultados del ensayo fundamental frontMIND fase 3 de la combinación tafasitamab (Monjuvi®/Minjuvi®) de Incyte presentados en el plenario del Congreso de la Asociación Europea de Hematología (EHA) 2026 revelaron una supervivencia prolongada libre de progresión Incyte (Nasdaq:INCY) anunció hoy resultados positivos del ensayo fundamental frontMIND fase 3 que evalúa la eficacia y la seguridad de tafasitamab (Monjuvi®/Minjuvi®), un anticuerpo monoclonal...

WILMINGTON, Del.--(BUSINESS WIRE)--  Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden, zeigten ein verlängertes progressionsfreies Überleben Incyte (Nasdaq:INCY) gab heute positive Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ bekannt, in der die Wirksamkeit und Sicherheit von Tafasitamab (Monj...